BIOGBs Stock Overview
A healthcare company, provides probiotic products worldwide. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
BioGaia AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 105.75 |
52 Week High | SEK 105.75 |
52 Week Low | SEK 93.63 |
Beta | 0.65 |
1 Month Change | 10.56% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | 5.33% |
5 Year Change | 5.54% |
Change since IPO | 140.34% |
Recent News & Updates
Recent updates
Shareholder Returns
BIOGBs | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 2.2% | 2.1% |
1Y | n/a | -14.2% | 1.8% |
Return vs Industry: Insufficient data to determine how BIOGBs performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BIOGBs performed against the UK Market.
Price Volatility
BIOGBs volatility | |
---|---|
BIOGBs Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: BIOGBs's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine BIOGBs's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 224 | Theresa Agnew | www.biogaia.com |
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula.
BioGaia AB (publ) Fundamentals Summary
BIOGBs fundamental statistics | |
---|---|
Market cap | SEK 10.76b |
Earnings (TTM) | SEK 309.74m |
Revenue (TTM) | SEK 1.42b |
Is BIOGBs overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOGBs income statement (TTM) | |
---|---|
Revenue | SEK 1.42b |
Cost of Revenue | SEK 385.91m |
Gross Profit | SEK 1.03b |
Other Expenses | SEK 723.54m |
Earnings | SEK 309.74m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 18, 2025
Earnings per share (EPS) | 3.06 |
Gross Margin | 72.81% |
Net Profit Margin | 21.83% |
Debt/Equity Ratio | 0% |
How did BIOGBs perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/20 05:06 |
End of Day Share Price | 2025/05/13 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioGaia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Christopher Uhde | ABG Sundal Collier Sponsored |
Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
Mattias Häggblom | Danske Bank |